Tactile Systems Technology Inc. (TCMD)
TCMD Stock Rises 20% in Three Months: Should You Buy, Hold or Sell?
Tactile Systems' top line reflects strong demand for its existing products. Workflow enhancements are driving efficiency.
Should Value Investors Buy Tactile Systems Technology (TCMD) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Are Investors Undervaluing Tactile Systems Technology (TCMD) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Tactile Systems Technology, Inc. (TCMD) Hit a 52 Week High, Can the Run Continue?
Tactile Systems Technology (TCMD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Tactile Medical to Present at the Piper Sandler 36th Annual Healthcare Conference
MINNEAPOLIS, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that management will participate in the Piper Sandler 36th Annual Healthcare Conference, which is being held at the Lotte New York Palace in New York, NY from December 3rd – 5th. Management will participate in a fireside chat on Tuesday, December 3rd at 10:00 a.m. Central Time.
Bull Of The Day: Tactile Systems Technology (TCMD)
Tactile Systems Technology (TCMD) is a Zacks Rank #2 (Buy) that has an A for Value and a C for Growth. The company develops medical devices for the treatment of chronic diseases at home.
Is Tactile Systems Technology (TCMD) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Wall Street Analysts Believe Tactile Systems Technology (TCMD) Could Rally 45.9%: Here's is How to Trade
The consensus price target hints at a 45.9% upside potential for Tactile Systems Technology (TCMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Tactile Systems Technology, Inc. (TCMD) Q3 2024 Earnings Call Transcript
Tactile Systems Technology, Inc. (NASDAQ:TCMD ) Q3 2024 Earnings Conference Call November 4, 2024 5:00 PM ET Company Participants Sam Bentzinger - Investor Relations, Gilmartin Group LLC Sheri Dodd - Chief Executive Officer Elaine Birkemeyer - Chief Financial Officer Conference Call Participants Kyle Bauser - B. Riley Operator Please standby.
Tactile Systems Technology (TCMD) Tops Q3 Earnings Estimates
Tactile Systems Technology (TCMD) came out with quarterly earnings of $0.24 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.85 per share a year ago.
Tactile Systems Technology, Inc. Reports Third Quarter 2024 Financial Results
MINNEAPOLIS, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the third quarter ended September 30, 2024 and announced the adoption of a share repurchase program. Third Quarter 2024 Summary & Recent Business Highlights: Total revenue increased 5% year-over-year to $73.1 million Lymphedema product revenue increased 4% over Q3 2023 Airway clearance product revenue increased 10% over Q3 2023 Net income of $5.2 million versus $22.3 million in Q3 2023 Adjusted EBITDA of $10.7 million versus $7.7 million in Q3 2023 Operating cashflow of $24.3 million year-to-date, compared to $17.5 million in the prior year period Ended Q3 2024 with $82.1 million in cash and cash equivalents Launched Nimbl, our next-generation lymphedema therapy platform for upper extremity conditions Announced publication of positive clinical trial results in VA lymphedema patients using Flexitouch therapy Authorized a program to repurchase up to $30.0 million of the Company's common stock “In the third quarter, we delivered solid gross margin expansion, drove continued improvements in profitability, and achieved double-digit growth in both our commercial and VA lymphedema channels,” said Sheri Dodd, President and Chief Executive Officer of Tactile Medical.
Tactile Systems Technology (TCMD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Tactile Systems Technology (TCMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
